The Department of Inorganic Chemistry guarantees the studies in the fields of Inorganic Chemistry, Bioinorganic Chemistry, and Chemistry for Teaching in bachelor's, master's and doctoral study programmes.


As a part of our research, we focus on the preparation and study of new coordination compounds of transition metals, in particular, on the development of new compounds with medicinal application potential (e.g. substances with antitumour, anti-inflammatory or antidiabetic activity or contrast agents for diagnostic imaging methods) or compounds with interesting magnetic, optical or catalytic properties with industrial application potential (e.g. high-density storage media, various types of sensors).

Our teaching activites, as a guarantor of Chemistry for Teaching studies at the Faculty of Science of Palacký University, are also focused on increasing pupils' and students' interest in science and motivation to study science, co-organizing chemical Olympics and also on extracurricular chemical activities for primary and secondary school students.

News

Invitation to Conference for PhD students in the didactics of chemistry

24. November 2025

On 28 and 29 November the Department of Inorganic Chemistry will organize XXI. Annual International Seminar of PhD students in the didactics of chemistry and other natural sciences. More deails including a program can be found below.

The full program in PDF format can be downloaded here.

The book of abstracts is available for download in PDF format here.

Publication in Inorganic Chemistry

Journal cover 24. November 2025

Publication entitled "Pentagonal Bipyramidal First-Row Transition Metal Complexes with Macrocyclic Ligand Containing Two Pyridine‑N‑Oxide Pendant Arms: Structural, Magnetic, and Theoretical Studies" (authors: B. Drahoš, I. Šalitroš, R. Herchel) has been published in the journal Inorganic Chemistry.

In this work, a heptadentate 15-membered pyridine-based macrocyclic ligand containing two pyridine-N-oxide pendant arms was synthesized
together with its first-row transition metal complexes with the general formula [M(L)](ClO4)2·1DMF (MII = Mn (1), Fe (2), Co (3), and Ni (4); DMF = N,N’-dimethylformamide). X-ray crystal structures revealed axially compressed pentagonal bipyramidal geometry with a coordination number of 7 for complexes 13 or 5 + 2 for complex 4. Fe(II), Co(II), and Ni(II) complexes 2, 3, and 4 show pronounced magnetic anisotropy (D = 4.47, 30.10, −7.58 cm−1, respectively).The complex 3 showed a field-induced single-molecule magnet behavior described best by the combination of direct (DHm = 145 K−1s−1) and Raman (C = 0.58 K−ns−1 for n = 5.76) relaxation processes. Magneto-structural correlation for Fe(II)/Co(II)/Ni(II) complexes with L and previously studied structurally similar ligands revealed a significant impact of the coordination ability of the functional group in pendant arms on the final magnetic anisotropy (π-acceptors appear to be more suitable).

Student publication in Dalton Transactions

Journal cover  30. September 2025

Student publication entitled "Computational insight into manganese(ii) complexes comprising macrocyclic ligands for magnetic resonance imaging" (authors: R. Herchel, M. Pražáková, B. Drahoš ) has been published in the chemistry journal Dalton Transactions.

This article was motivated by the increased interest in MRI contrast agents based on manganese coordination compounds. Herein,  23 manganate complexes with macrocyclic ligands were selected and divided into five groups depending on the structural nature of the macrocyclic ligand. Using the DFT method and two solvation models (CPCM and SMD), stability constants (log KMnL) were calculated for all complexes as well as hyperfine splitting constants A(17O), zero-field splitting parameters (ZFS) and they were compared with experimental data. These results represent the first step in predicting the properties of interest, which could significantly facilitate the design of new MRI contrast agents.

Czech Patent granted

10. September 2025

A patent titled "Coordination osmium compounds to be used in the treatment of pulmonary cancer" (inventors: J. Hošek, I. Nemec, P. Štarha) was granted to a team of inventors consisting of members from the Department of Inorganic Chemistry at Palacký University in Olomouc and the Veterinary Research Institute in Brno. The patent protects a class of ionic half-sandwich osmium(II) complexes with derivatives of ethane-1,2-diamine substituted with two polyaromatic groups. This protection covers their use in treating cancer diseases (specifically lung cancer), as well as the method for preparing these compounds and the pharmaceutical formulations containing them.

Publication in European Journal of Medicinal Chemistry

Journal cover 13. August 2025

Publication entitled "Highly effective Ru(II) and Os(II) half-sandwich complexes induce cytotoxicity in cancer cells through combined mitochondrial and endoplasmic reticulum stress" (authors: J. Hošek, K. Petrželová, R. Héžová, N. Straková, S. Kajabová, I. Nemec, P. Šimečková, K. Pěnčíková, J. Mašek, J. Moncoľ, P. Štarha) has been published in the journal European Journal of Medicinal Chemistry.

This work describes a series of half-sandwich Ru(II) and Os(II) complexes containing ethane-1,2-diamine-based Schiff bases substituted with polycyclic aromatic hydrocarbons (PAHs). The compounds studied were designed to combine the mechanisms of action of half-sandwich complexes (redox process modulation, reactive oxygen species formation) with the ability of PAH substituents to interact with DNA. Biological tests demonstrated that the complexes studied possess significant antiproliferative activity against various lung cancer cell lines, including those resistant to cisplatin. Treatment with these complexes led to the activation of stress-related signalling pathways, including unconventional endoplasmic reticulum stress, apoptotic signalling, and mitochondrial membrane depolarization. Activation of the p21/GADD45A signalling pathway also indicates a DNA damage response. The results highlight the potential of these compounds as alternative metallodrugs capable of overcoming cisplatin resistance and minimizing side effects.

Privacy settings

We use cookies and any other network identifiers on our website that may contain personal data (e.g. about how you browse our website). We and some of the service providers we use have access to or store this data on your device. This data helps us to operate and improve our services. For some purposes, your consent is required to process data collected in this way. You can change or revoke your consent at any time (see the link at the bottom the page).

(Essential cookies enable basic functions and are necessary for the website to function properly.)
(Statistics cookies collect information anonymously. This information helps us to understand how our visitors use our website.)
(They are designed for promotional purposes, measuring the success of promotional campaigns, etc.)